Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs MobilEye Global Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.89 (market cap $6.04B), while MobilEye Global Inc trades at $7.15 (market cap $6.00B). The key difference: Iovance Biotherapeutics Inc. Common Stock and MobilEye Global Inc are close in size by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and MobilEye Global Inc for 15 Days on average.
| IOVA | MBLY | |
|---|---|---|
Market Cap | $6.04B | $6.00B |
Volume | 14,805,993 | 7,007,849 |
Sector | Health | Consumer Cyclical |
52-Week High | $14.82 | $15.42 |
52-Week Low | $1.81 | $6.56 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $5.97B | $4.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Mobileye (MBLY) trades at $7.15, down 4.28% today, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported revenue growth to $1.89B in 2025 but posted a significant net loss of -$392M, with profitability metrics remaining negative. Recent news highlights ADAS business momentum and strategic investments in autonomous mobility, while analyst consensus remains positive with a $10.83 price target.
The stock presents a high-risk opportunity with strong analyst support but persistent profitability challenges. Upside potential exists from autonomous driving adoption and new program ramps, offset by execution risks and negative cash flow projections for 2026. Current valuation below book value offers margin of safety for long-term investors willing to withstand volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
